In brief: O2 Concepts enters EU, Remsleep hires Stelzner, Edgepark adds CGMs 

MIDDLEBURY, Conn. - O2 Concepts has received medical device regulation (MDR) certification for its Oxlife Liberty POC and Oxlife Independence POC with DNA Technology. The certification gives the company the ability to market and distribute the devices across the European Union member countries. “For us, MDR approval is more than expanding into new markets — it is a reflection of our company’s high standards for our POCs in clinical efficacy and reliable performance,” said Elby Beal, CEO of O2 Concepts. “We are in the innovation business, designing and building advanced portable oxygen devices that perform better and over a longer term for our customers and patients." To support its European expansion, O2 Concepts is partnering with leading distributors to bring Oxlife devices to high-demand EU markets. With MDR approval in Europe and recent MDSAP approval for Health Canada, the company says it is well-positioned to meet growing global demand for its portable oxygen solutions. 

• Related: Paul Miller sees much of his new role at O2 Concepts as bringing organization and support to a company with both a strong sales team and product portfolio   

Medline helps Iowa Ortho streamline operations, improve procurement 

NORTHFIELD, Ill. - Medline has announced a prime vendor agreement with Des Moines, Iowa-based Iowa Ortho, which offers medical evaluations and medical care for a wide variety of areas ranging from general orthopedics to sports medicine to neck and spine. Under the agreement, Iowa Ortho has: 

• Access to Medline’s portfolio of products and data to help drive increased standardization, operational efficiency and cost savings across the organization 
• The added stability to acquire the products it needs to deliver care and proactive communication on price changes, backorder updates, inventory tracking and reporting to guide its strategic business decisions. 

“Efficiency and reliability in our supply chain are critical to maintaining the high level of care our patients expect,” said Julie Walker, clinical operations manager at Iowa Ortho. “This partnership with Medline gives us greater visibility into our procurement operations, helps us manage costs and allows our staff to stay focused on what matters most – exceptional patient outcomes.” Iowa Ortho, which has 14 locations in the state, has served patients in the metro Des Moines area for more than 70 years. Its 26 specialty physicians offer a variety of services and procedures to meet the diverse needs of patients, including injectable therapy, surgery, casting/bracing and imaging. “Supporting Iowa Ortho means working with a team that’s deeply invested in providing the latest care focused on their patients,” said Brenna Hansen, physician office representative at Medline. “We’re proud to provide the tools, data and flexibility they need to stay ahead in a rapidly evolving health care landscape.” 

Remote monitoring helps COPD patients stay out of hospital 

YARMOUTH, Maine – Researchers have found that telehealth-supported oxygen therapy significantly reduced hospital readmissions. A systematic review and meta-analysis published in the Journal of Medical Internet Research evaluated the clinical effectiveness of remote monitoring and digital communication for home oxygen therapy in patients with COPD. The analysis included eight randomized controlled trials encompassing a total of 1,275 patients and compared telehealth support and usual care. Findings included: 

• Hospital readmissions: Researchers found that telehealth-supported oxygen therapy significantly reduced hospital readmissions. The analysis showed a moderate effect size, indicating that remote monitoring and timely intervention can prevent exacerbations requiring hospitalization. 
• Health-related quality of life: Patients receiving telehealth support reported noticeable improvements in their quality of life, reflecting better symptom management, greater confidence in self-care and enhanced overall well-being. 
• Adherence to oxygen therapy: Despite improvements in other areas, telehealth support did not significantly improve adherence to prescribed oxygen use. The lack of effect on adherence highlights the need for tailored behavioral interventions alongside telehealth tools. 

The review also evaluated the cost-effectiveness of telehealth-supported interventions. Researchers found that, although initial costs were higher due to technology and setup, these interventions showed potential for long-term savings by reducing hospital stays and associated health care expenses. 

Edgepark adds two CGMs to portfolio 

TWINSBURG, Ohio – Edgepark has expanded its portfolio to include the latest innovations from diabetes manufacturers, including a glucose biosensor that can be purchased without a prescription and a yearlong continuous glucose monitor system. "Our goal is to meet patients where they are in their health journey," said Anthony Alvarez, SVP and GM of Edgepark. "Diabetes is one of the fastest-growing conditions in the United States, and the introduction of innovations like (these) will no doubt play a pivotal role in the well-being of the patients we serve."  

Dexcom Stelo Glucose Biosensor System (Stelo) 

Edgepark is now one of a limited number of suppliers to offer the Dexcom Stelo, the first-ever FDA-cleared, over-the-counter glucose biosensor. This biosensor expands access to this technology to adults not on insulin and who don't have a history of problematic hypoglycemia. This accessibility, coupled with the ability to provide glucose insights directly to a smartphone without fingersticks, empowers a wider population to proactively understand and manage their metabolic health, the company says. This product is FSA/HSA eligible and can be ordered without a prescription from a health care provider here. 

"While CGMs have become more accessible through insurance in recent years, there are still many people who do not qualify for coverage – that's where over-the-counter options like the Stelo biosensor come into play," said Alvarez. "At Edgepark, we are laser-focused on overcoming accessibility challenges to help patients manage overall health and make more proactive decisions throughout their day." 

Eversense 365 Continuous Glucose Monitoring 

Edgepark is also offering the Eversense 365, the first and only FDA-cleared one-year implantable CGM system, intended for use in those living with Type 1 or Type 2 diabetes who are 18 and older. This product is inserted only once a year into the upper arm by a health care provider to provide continuous monitoring for 365 days. 

RemSleep hires Stelzner, prepares Deltawave push 

CLEARWATER, Fla. - RemSleep has announced that John Stelzner, a former vice president of marketing for a major manufacturer, is coming out of retirement to lead strategic marketing and brand development for its Deltawave CPAP Mask System. RemSleep says after reviewing product samples and hearing firsthand feedback from users, Stelzner agreed to join the company in a formal capacity to shape its messaging, launch strategy and long-term market presence. "When I saw what Deltawave could do and heard how it changed someone's sleep in just one night, I knew I wanted to be part of it," he said. "This product doesn't just challenge traditional CPAP design. It offers a new standard of comfort rooted in real science." Stelzner will develop a sales channel for the Deltawave in the home medical equipment (HME) space, including building an independent nationwide sales team, helping with key customers, finding a government channel distributor and setting up policies and procedures that are focused the channel. Deltawave is a patented CPAP interface cleared by the U.S. Food and Drug Administration. It is designed to restore natural breathing rhythms without pressure resistance, facial strain or humidification. Stelzner, according to his LinkedIn profile, has previously worked at ABM Respiratory Care and Philips Respironics. 

• Related: Earlier this year, RemSleep entered into an agreement with www.1800CPAP.com  to distribute the Deltawave nationwide. 

Numotion honored for disability inclusion 

BRENTWOOD, Tenn. - Numotion has been named a “Best Place to Work for Disability Inclusion” for the fifth consecutive year. The award is based on the company’s 2025 score of 100 on the Disability Equality Index (DEI). “Being named a Best Place to Work for Disability Inclusion for the fifth year in a row is a meaningful milestone and a testament to our continued commitment to inclusion,” said Mike Swinford, CEO of Numotion. “At Numotion, we believe that an inclusive workplace benefits everyone. We are proud to foster a culture where employees of all abilities can thrive, and where our mission to improve the lives of people living with disabilities is reflected not just in what we do for our customers but also in how we support and empower our team members.” The DEI evaluates companies across categories such as culture and leadership, enterprise-wide access, employment practices, community engagement and supplier diversity. Companies that earn a top score of 100 are recognized as DEI Best Places to Work for Disability Inclusion. The Disability Equality Index is a joint initiative of the American Association of People with Disabilities (AAPD) and Disability:IN. It is recognized as the most robust disability inclusion assessment tool designed to help companies build a roadmap of measurable, tangible actions that create an inclusive workplace.